董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Walter Hanna, Jr. | -- | Director, President and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-10-22 |
| R. Bryan Riggsbee | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-22 |
| Arthur A. Torres | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-22 |
| Hannah A. Valantine | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-22 |
| Suresh Gunasekaran | 男 | Director | 50 | 未披露 | 未持股 | 2025-10-22 |
| Christine M. Cournoyer | 女 | Independent Director | 73 | 23.26万美元 | 未持股 | 2025-10-22 |
| Fred E. Cohen | 男 | Independent Director | 68 | 23.46万美元 | 未持股 | 2025-10-22 |
| Peter Maag | 男 | Independent Director | 58 | 640.00万美元 | 未持股 | 2025-10-22 |
| George W. Bickerstaff, III | 男 | Independent Director | 69 | 23.76万美元 | 未持股 | 2025-10-22 |
| Michael D. Goldberg | 男 | Chairman of the Board | 67 | 32.36万美元 | 未持股 | 2025-10-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nathan Smith | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2025-10-22 |
| John Walter Hanna, Jr. | -- | Director, President and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-10-22 |
| Jessica Meng | -- | Chief Commercial Officer | -- | 未披露 | 未持股 | 2025-10-22 |
| Keith Kennedy | -- | Chief Operating Officer | -- | 未披露 | 未持股 | 2025-10-22 |
| Jeff Novack | -- | General Counsel and Secretary | -- | 未披露 | 未持股 | 2025-10-22 |
董事简历
中英对照 | 中文 | 英文- John Walter Hanna, Jr.
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- R. Bryan Riggsbee
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Arthur A. Torres
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Hannah A. Valantine
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Suresh Gunasekaran
-
Suresh Gunasekaran，自2022年3月起担任国际公认的卫生系统UCSF Health的首席执行官兼总裁。在加入UCSF Health之前，Gunasekaran先生曾于2018年12月至2022年2月担任爱荷华大学医院和诊所的首席执行官和爱荷华大学医疗保健副总裁。Gunasekaran先生此前于2017年10月至2018年11月担任西南卫生资源Population Health服务公司高级主管。在加入Southwestern Health Resources Population Health服务公司之前，Gunasekaran先生曾于2004年9月至2018年11月在犹他州西南医疗中心担任超过十四年的职责增加，于2004年9月至2014年12月担任该中心的副总裁，负责大学医院和诊所的卫生系统事务和首席信息官，并于2015年至2018年11月担任卫生系统的首席运营官。Gunasekaran先生拥有范德比尔特大学学士学位和南方卫理公会大学工商管理硕士学位。
Suresh Gunasekaran,has served as the Chief Executive Officer and President of UCSF Health, an internationally recognized health system, since March 2022. Prior to UCSF Health, Mr. Gunasekaran served as the CEO of University of Iowa Hospitals & Clinics and the Associate Vice President of University of Iowa Health Care from December 2018 to February 2022. Mr. Gunasekaran previously served as the Senior Executive Officer of Southwestern Health Resources Population Health Services Company from October 2017 to November 2018. Prior to Southwestern Health Resources Population Health Services Company, Mr. Gunasekaran served in roles of increasing responsibility over fourteen years with UT Southwestern Medical Center, from September 2004 to November 2018, where he served as its Associate Vice President, Health System Affairs & CIO, University Hospitals & Clinics from September 2004 to December 2014 and its Chief Operations Officer, Health System from 2015 to November 2018. Mr. Gunasekaran holds a bachelor's degree from Vanderbilt University and an M.B.A. from Southern Methodist University. - Suresh Gunasekaran，自2022年3月起担任国际公认的卫生系统UCSF Health的首席执行官兼总裁。在加入UCSF Health之前，Gunasekaran先生曾于2018年12月至2022年2月担任爱荷华大学医院和诊所的首席执行官和爱荷华大学医疗保健副总裁。Gunasekaran先生此前于2017年10月至2018年11月担任西南卫生资源Population Health服务公司高级主管。在加入Southwestern Health Resources Population Health服务公司之前，Gunasekaran先生曾于2004年9月至2018年11月在犹他州西南医疗中心担任超过十四年的职责增加，于2004年9月至2014年12月担任该中心的副总裁，负责大学医院和诊所的卫生系统事务和首席信息官，并于2015年至2018年11月担任卫生系统的首席运营官。Gunasekaran先生拥有范德比尔特大学学士学位和南方卫理公会大学工商管理硕士学位。
- Suresh Gunasekaran,has served as the Chief Executive Officer and President of UCSF Health, an internationally recognized health system, since March 2022. Prior to UCSF Health, Mr. Gunasekaran served as the CEO of University of Iowa Hospitals & Clinics and the Associate Vice President of University of Iowa Health Care from December 2018 to February 2022. Mr. Gunasekaran previously served as the Senior Executive Officer of Southwestern Health Resources Population Health Services Company from October 2017 to November 2018. Prior to Southwestern Health Resources Population Health Services Company, Mr. Gunasekaran served in roles of increasing responsibility over fourteen years with UT Southwestern Medical Center, from September 2004 to November 2018, where he served as its Associate Vice President, Health System Affairs & CIO, University Hospitals & Clinics from September 2004 to December 2014 and its Chief Operations Officer, Health System from 2015 to November 2018. Mr. Gunasekaran holds a bachelor's degree from Vanderbilt University and an M.B.A. from Southern Methodist University.
- Christine M. Cournoyer
-
ChristineM.Cournoyer于2020年3月成为公司董事。职位，主要职业和专业经验:Cournoyer女士自2019年起担任Digital Health Companies的战略顾问以及为移植患者提供解决方案的领先精准医疗公司CareDx，Inc.的董事会成员。她曾于2012年至2019年担任N-of-One，Inc.的首席执行官兼主席，直到该公司被QiagenN.V.收购，并在2019年剩余时间担任其战略顾问。在她担任N-of-One，Inc.的首席执行官期间。Cournoyer女士领导了从患者礼宾业务到销售给大型健康供应商和领先的分子诊断商业实验室的领先分子决策支持公司的转型。在她的团队的努力下，她创建了一个运行在云中的符合HIPAA标准的平台，该平台可扩展到解释数十万次分子诊断测试。从2010年到2011年，Cournoyer女士担任United-Health Group/Optum的临床分析副总裁，在那里她负责临床解决方案并定义临床支持策略。从2006年到2010年，她曾担任Picis公司（梦百合IT的全球领导者）的总裁兼首席运营官。Cournoyer女士还于2012年至2018年担任Emerson Hospital的董事会成员，2008年至2011年担任BJ’s Wholesale Club的董事会成员，2001年至2007年担任Stride Rite的董事会成员，2003年至2006年担任GTech的董事会成员。曾担任Harte Hanks的数据库部门董事总经理、IBM Software Group的全球业务转型和首席信息官副总裁。她持有the University of Massachusetts的工商管理B.S.学位、Northeastern University的经济学硕士学位，也是麻省理工学院高管教育项目的毕业生。
Christine M. Cournoyer has served as a member of Board of Directors since September 2019. From 2012 to 2019 Ms. Cournoyer served as the Chairperson and Chief Executive Officer for N-of-One, Inc., a leading company in precision medicine delivering clinical and molecular decision support for targeted therapies decisions based on a cancer patient's molecular profile. Prior to joining N-of-One, Ms. Cournoyer was the Vice President of Clinical Analytics at Optum, responsible for clinical electronic health records solutions and clinical decision support solutions. Prior to joining Optum through the acquisition of Picis, Inc. in 2010 Ms. Cournoyer was the President and Chief Operating Officer for Picis, a company in the healthcare IT market offering digital solutions to automate the clinical and revenue cycle workflows for the high acuity operations of hospitals. Prior to Picis, Ms. Cournoyer was responsible for all analytical solutions serving the retail industry at Harte Hanks, Inc. Ms. Cournoyer has also held roles at Lotus and IBM. At Lotus, she was the Chief Information Officer. At IBM, she was Vice President of Global Business Transformation, responsible for driving the digital strategy for global software fulfillment for the $8 billion software business. Ms. Cournoyer has served on a variety of boards over the last 20 years, including The Stride Rite Corporation, GTECH Corporation, BJ's Wholesale Club, Inc. and Emerson Hospital. She has also served as a director of Spok Holdings, Inc., a leader in the field of clinical communications, since March 2020. Ms. Cournoyer holds a B.S in Business Administration from University of Massachusetts, an M.A. in Economics from Northeastern University and has attended MIT's Executive Education Program. - ChristineM.Cournoyer于2020年3月成为公司董事。职位，主要职业和专业经验:Cournoyer女士自2019年起担任Digital Health Companies的战略顾问以及为移植患者提供解决方案的领先精准医疗公司CareDx，Inc.的董事会成员。她曾于2012年至2019年担任N-of-One，Inc.的首席执行官兼主席，直到该公司被QiagenN.V.收购，并在2019年剩余时间担任其战略顾问。在她担任N-of-One，Inc.的首席执行官期间。Cournoyer女士领导了从患者礼宾业务到销售给大型健康供应商和领先的分子诊断商业实验室的领先分子决策支持公司的转型。在她的团队的努力下，她创建了一个运行在云中的符合HIPAA标准的平台，该平台可扩展到解释数十万次分子诊断测试。从2010年到2011年，Cournoyer女士担任United-Health Group/Optum的临床分析副总裁，在那里她负责临床解决方案并定义临床支持策略。从2006年到2010年，她曾担任Picis公司（梦百合IT的全球领导者）的总裁兼首席运营官。Cournoyer女士还于2012年至2018年担任Emerson Hospital的董事会成员，2008年至2011年担任BJ’s Wholesale Club的董事会成员，2001年至2007年担任Stride Rite的董事会成员，2003年至2006年担任GTech的董事会成员。曾担任Harte Hanks的数据库部门董事总经理、IBM Software Group的全球业务转型和首席信息官副总裁。她持有the University of Massachusetts的工商管理B.S.学位、Northeastern University的经济学硕士学位，也是麻省理工学院高管教育项目的毕业生。
- Christine M. Cournoyer has served as a member of Board of Directors since September 2019. From 2012 to 2019 Ms. Cournoyer served as the Chairperson and Chief Executive Officer for N-of-One, Inc., a leading company in precision medicine delivering clinical and molecular decision support for targeted therapies decisions based on a cancer patient's molecular profile. Prior to joining N-of-One, Ms. Cournoyer was the Vice President of Clinical Analytics at Optum, responsible for clinical electronic health records solutions and clinical decision support solutions. Prior to joining Optum through the acquisition of Picis, Inc. in 2010 Ms. Cournoyer was the President and Chief Operating Officer for Picis, a company in the healthcare IT market offering digital solutions to automate the clinical and revenue cycle workflows for the high acuity operations of hospitals. Prior to Picis, Ms. Cournoyer was responsible for all analytical solutions serving the retail industry at Harte Hanks, Inc. Ms. Cournoyer has also held roles at Lotus and IBM. At Lotus, she was the Chief Information Officer. At IBM, she was Vice President of Global Business Transformation, responsible for driving the digital strategy for global software fulfillment for the $8 billion software business. Ms. Cournoyer has served on a variety of boards over the last 20 years, including The Stride Rite Corporation, GTECH Corporation, BJ's Wholesale Club, Inc. and Emerson Hospital. She has also served as a director of Spok Holdings, Inc., a leader in the field of clinical communications, since March 2020. Ms. Cournoyer holds a B.S in Business Administration from University of Massachusetts, an M.A. in Economics from Northeastern University and has attended MIT's Executive Education Program.
- Fred E. Cohen
-
Fred E. Cohen，自2018年9月起担任Kyverna Therapeutics， Inc.董事会成员。自2017年11月以来，Cohen博士一直担任Vida Ventures（他于2017年共同创立的风险投资公司）的高级常务董事。他也曾担任Monograph Capital Partners（生物技术风险投资基金）的联合创始人兼董事长（2021年7月以来）。他目前担任TPG的高级顾问，在那里他曾担任TPG Biotechnology（生命科学风险投资基金）的合伙人和创始人（从2001年到2016年）。Cohen博士也是私人持有的Cell Design Labs的联合创始人兼执行主席，该公司于2017年12月被Gilead Sciences， Inc.（纳斯达克股票代码：GILD）收购。从1980年到2014年，Cohen博士在加州大学旧金山分校（UCSF）担任研究科学家、住院患者内科医生、咨询内分泌学家、内分泌学和代谢科主任等职务。他的研究兴趣包括基于结构的药物设计、朊病毒疾病、计算生物学和杂多聚合物化学。Cohen博士发表了200多篇同行评议文章，作为10多项专利的共同发明人参与，并担任多个国际科学期刊的编辑或编辑委员会成员。他持有Yale University的分子生物物理学和生物化学学士学位。他获得了斯坦福大学的医学博士学位，并在UCSF接受了内科和内分泌学的博士后和研究生医学培训。他是美国医师学会和美国医学信息学学会的成员，也是美国临床研究学会和美国医师协会的成员。Cohen博士因其工作获得了多个奖项，包括Searle奖学金、内分泌学会和西方临床研究学会颁发的青年研究者奖，以及LVMH Science pour l’art奖（与Stanley Prusiner共享）。科恩博士于2004年当选为美国国家医学院院士，2008年当选为美国艺术与科学学院院士。Cohen博士目前担任多个生物技术和制药组织的董事会成员，包括CareDx， Inc.（纳斯达克代码：CDNA）， Progyny, Inc.（纳斯达克代码：PGNY）， Intellia Therapeutics, Inc.（纳斯达克代码：NTLA）和UroGen Pharma Ltd.（纳斯达克代码：URGN）。他是Quintiles Transnational（与IQVIA Holdings（纽约证券交易所代码：IQV）合并）、Biocryst（纳斯达克代码：BCRX）、Genomic Health（被Exact Sciences Corp.收购）（纳斯达克代码：GHDX）、Tandem Diabetes Care, Inc.（纳斯达克代码：TNDM）、Five Prime Therapeutics, Inc.（纳斯达克代码：FPRX，被Amgen Inc.收购）、Roka Biosciences（纳斯达克代码：Roka）和Veracyte， Inc.（纳斯达克代码：VCYT）的前任董事会成员。
Fred E. Cohen,has served as a member of Kyverna Therapeutics, Inc. board of directors since September 2018. Since November 2017, Dr. Cohen has served as a Senior Managing Director of Vida Ventures, a venture capital firm that he co-founded in 2017. Dr. Cohen has also served as a co-founder and Chairman of Monograph Capital Partners, a biotechnology venture capital fund, since July 2021. Dr. Cohen currently serves as a Senior Advisor to TPG, where he previously served as a Partner and founder of TPG Biotechnology, a life science venture capital fund, from 2001 to 2016. Dr. Cohen was also a co-founder and executive chairperson of privately held Cell Design Labs, which was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) in December 2017. From 1980 through 2014, Dr. Cohen was at the University of California, San Francisco (UCSF), where he held various responsibilities as a research scientist, an Internist for hospitalized patients, a consulting Endocrinologist, and as the Chief of the Division of Endocrinology and Metabolism. Dr. Cohen's research interests included structure based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen has published over 200 peer reviewed articles, participated as a co-inventor on over 10 patents and has served as an editor or editorial board member of several international scientific journals. Dr. Cohen received his Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from the University of Oxford on a Rhodes Scholarship, his MD from Stanford University and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen has received several awards for his work including a Searle Scholarship, Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation, and the LVMH Science pour l'art prize (shared with Stanley Prusiner). Dr. Cohen was elected to the National Academy of Medicine in 2004 and the American Academy of Arts and Sciences in 2008. Dr. Cohen currently serves on the Board of Directors of several biotechnology and pharmaceutical organizations, including CareDx, Inc. (Nasdaq: CDNA), Progyny, Inc. (Nasdaq: PGNY), Intellia Therapeutics, Inc. (Nasdaq: NTLA) and UroGen Pharma Ltd. (Nasdaq: URGN). He is a past member of the boards of Quintiles Transnational (merged with IQVIA Holdings (NYSE: IQV)), Biocryst (Nasdaq: BCRX), Genomic Health (acquired by Exact Sciences Corp.) (Nasdaq: GHDX), Tandem Diabetes Care, Inc. (Nasdaq: TNDM), Five Prime Therapeutics, Inc. (Nasdaq: FPRX, acquired by Amgen Inc.), Roka Biosciences (Nasdaq: ROKA), and Veracyte, Inc. (Nasdaq: VCYT). - Fred E. Cohen，自2018年9月起担任Kyverna Therapeutics， Inc.董事会成员。自2017年11月以来，Cohen博士一直担任Vida Ventures（他于2017年共同创立的风险投资公司）的高级常务董事。他也曾担任Monograph Capital Partners（生物技术风险投资基金）的联合创始人兼董事长（2021年7月以来）。他目前担任TPG的高级顾问，在那里他曾担任TPG Biotechnology（生命科学风险投资基金）的合伙人和创始人（从2001年到2016年）。Cohen博士也是私人持有的Cell Design Labs的联合创始人兼执行主席，该公司于2017年12月被Gilead Sciences， Inc.（纳斯达克股票代码：GILD）收购。从1980年到2014年，Cohen博士在加州大学旧金山分校（UCSF）担任研究科学家、住院患者内科医生、咨询内分泌学家、内分泌学和代谢科主任等职务。他的研究兴趣包括基于结构的药物设计、朊病毒疾病、计算生物学和杂多聚合物化学。Cohen博士发表了200多篇同行评议文章，作为10多项专利的共同发明人参与，并担任多个国际科学期刊的编辑或编辑委员会成员。他持有Yale University的分子生物物理学和生物化学学士学位。他获得了斯坦福大学的医学博士学位，并在UCSF接受了内科和内分泌学的博士后和研究生医学培训。他是美国医师学会和美国医学信息学学会的成员，也是美国临床研究学会和美国医师协会的成员。Cohen博士因其工作获得了多个奖项，包括Searle奖学金、内分泌学会和西方临床研究学会颁发的青年研究者奖，以及LVMH Science pour l’art奖（与Stanley Prusiner共享）。科恩博士于2004年当选为美国国家医学院院士，2008年当选为美国艺术与科学学院院士。Cohen博士目前担任多个生物技术和制药组织的董事会成员，包括CareDx， Inc.（纳斯达克代码：CDNA）， Progyny, Inc.（纳斯达克代码：PGNY）， Intellia Therapeutics, Inc.（纳斯达克代码：NTLA）和UroGen Pharma Ltd.（纳斯达克代码：URGN）。他是Quintiles Transnational（与IQVIA Holdings（纽约证券交易所代码：IQV）合并）、Biocryst（纳斯达克代码：BCRX）、Genomic Health（被Exact Sciences Corp.收购）（纳斯达克代码：GHDX）、Tandem Diabetes Care, Inc.（纳斯达克代码：TNDM）、Five Prime Therapeutics, Inc.（纳斯达克代码：FPRX，被Amgen Inc.收购）、Roka Biosciences（纳斯达克代码：Roka）和Veracyte， Inc.（纳斯达克代码：VCYT）的前任董事会成员。
- Fred E. Cohen,has served as a member of Kyverna Therapeutics, Inc. board of directors since September 2018. Since November 2017, Dr. Cohen has served as a Senior Managing Director of Vida Ventures, a venture capital firm that he co-founded in 2017. Dr. Cohen has also served as a co-founder and Chairman of Monograph Capital Partners, a biotechnology venture capital fund, since July 2021. Dr. Cohen currently serves as a Senior Advisor to TPG, where he previously served as a Partner and founder of TPG Biotechnology, a life science venture capital fund, from 2001 to 2016. Dr. Cohen was also a co-founder and executive chairperson of privately held Cell Design Labs, which was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) in December 2017. From 1980 through 2014, Dr. Cohen was at the University of California, San Francisco (UCSF), where he held various responsibilities as a research scientist, an Internist for hospitalized patients, a consulting Endocrinologist, and as the Chief of the Division of Endocrinology and Metabolism. Dr. Cohen's research interests included structure based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen has published over 200 peer reviewed articles, participated as a co-inventor on over 10 patents and has served as an editor or editorial board member of several international scientific journals. Dr. Cohen received his Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from the University of Oxford on a Rhodes Scholarship, his MD from Stanford University and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen has received several awards for his work including a Searle Scholarship, Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation, and the LVMH Science pour l'art prize (shared with Stanley Prusiner). Dr. Cohen was elected to the National Academy of Medicine in 2004 and the American Academy of Arts and Sciences in 2008. Dr. Cohen currently serves on the Board of Directors of several biotechnology and pharmaceutical organizations, including CareDx, Inc. (Nasdaq: CDNA), Progyny, Inc. (Nasdaq: PGNY), Intellia Therapeutics, Inc. (Nasdaq: NTLA) and UroGen Pharma Ltd. (Nasdaq: URGN). He is a past member of the boards of Quintiles Transnational (merged with IQVIA Holdings (NYSE: IQV)), Biocryst (Nasdaq: BCRX), Genomic Health (acquired by Exact Sciences Corp.) (Nasdaq: GHDX), Tandem Diabetes Care, Inc. (Nasdaq: TNDM), Five Prime Therapeutics, Inc. (Nasdaq: FPRX, acquired by Amgen Inc.), Roka Biosciences (Nasdaq: ROKA), and Veracyte, Inc. (Nasdaq: VCYT).
- Peter Maag
-
Peter Maag自2012年11月起担任CareDx公司董事会成员，自2020年11月起担任CareDx公司执行主席。Maag博士还于2012年10月至2020年11月担任CareDx公司首席执行官，并于2012年10月至2018年11月担任CareDx公司总裁。在加入公司之前，2001年9月至2012年4月，Maag博士在Novartis International AG（一家全球医疗保健公司）担任多个职位，责任越来越大，包括2009年至2012年担任Novartis Diagnostics （Novartis a.g。的业务部门）的全球主管。2006年至2008年，Maag博士担任Novartis Pharma AG在德国的国家总裁，2003年至2005年担任Novartis韩国业务的国家总裁，2001年至2002年担任Novartis A.G。制药部门的战略主管。从1995年到2001年，Maag博士还在McKinsey & Company工作，专注于医疗保健和全球化。除了支持各种医疗保健和科技公司的增长努力外，Maag博士还担任Phoenix Pharma SE的董事会职务，并在华盛顿特区的个性化医疗联盟董事会任职。Maag博士在海德堡大学和伦敦大学学习制药科学，并在德国柏林大学获得博士学位。
Peter Maag,has served as Kyverna Therapeutics, Inc. Chief Executive Officer since October 2022. Dr. Maag is a seasoned global industry executive with a track record of transforming organizations and more than 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining Kyverna, Dr. Maag was Executive Chairman of CareDx, Inc. (Nasdaq: CDNA) from November 2020 to November 2021 and Chief Executive Officer and President of CareDx from October 2012 to November 2020, where he built the company from a small start-up into a public company and industry-leading transplantation company through a series of BD&L and financing transactions. Prior to joining CareDx, Dr. Maag held multiple positions at Novartis with increasing responsibilities. As President, Novartis Diagnostics, he drove growth and innovation in its blood-screening business. Prior to that, he led one of Novartis' key affiliates as country president, Germany, and lived in a dynamically growing market as Country President, Korea. At headquarters in Switzerland, he served as the head of strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise. Prior to joining Novartis, Dr. Maag worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. In addition to supporting various healthcare and tech companies in their growth efforts, he holds board and advisory positions at Phoenix Pharma SE, CareDx, Inc. (Nasdaq: CDNA), and the Personalized Medicine Coalition. He previously served on the board of directors of MiroMatrix Medical Inc. (Nasdaq: MIRO) from June 2021 until it was acquired by United Therapeutics Corporation in December 2023. Dr. Maag received his PhD from the University of Berlin, Germany, and studied pharmaceutical sciences in Heidelberg and London. - Peter Maag自2012年11月起担任CareDx公司董事会成员，自2020年11月起担任CareDx公司执行主席。Maag博士还于2012年10月至2020年11月担任CareDx公司首席执行官，并于2012年10月至2018年11月担任CareDx公司总裁。在加入公司之前，2001年9月至2012年4月，Maag博士在Novartis International AG（一家全球医疗保健公司）担任多个职位，责任越来越大，包括2009年至2012年担任Novartis Diagnostics （Novartis a.g。的业务部门）的全球主管。2006年至2008年，Maag博士担任Novartis Pharma AG在德国的国家总裁，2003年至2005年担任Novartis韩国业务的国家总裁，2001年至2002年担任Novartis A.G。制药部门的战略主管。从1995年到2001年，Maag博士还在McKinsey & Company工作，专注于医疗保健和全球化。除了支持各种医疗保健和科技公司的增长努力外，Maag博士还担任Phoenix Pharma SE的董事会职务，并在华盛顿特区的个性化医疗联盟董事会任职。Maag博士在海德堡大学和伦敦大学学习制药科学，并在德国柏林大学获得博士学位。
- Peter Maag,has served as Kyverna Therapeutics, Inc. Chief Executive Officer since October 2022. Dr. Maag is a seasoned global industry executive with a track record of transforming organizations and more than 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining Kyverna, Dr. Maag was Executive Chairman of CareDx, Inc. (Nasdaq: CDNA) from November 2020 to November 2021 and Chief Executive Officer and President of CareDx from October 2012 to November 2020, where he built the company from a small start-up into a public company and industry-leading transplantation company through a series of BD&L and financing transactions. Prior to joining CareDx, Dr. Maag held multiple positions at Novartis with increasing responsibilities. As President, Novartis Diagnostics, he drove growth and innovation in its blood-screening business. Prior to that, he led one of Novartis' key affiliates as country president, Germany, and lived in a dynamically growing market as Country President, Korea. At headquarters in Switzerland, he served as the head of strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise. Prior to joining Novartis, Dr. Maag worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. In addition to supporting various healthcare and tech companies in their growth efforts, he holds board and advisory positions at Phoenix Pharma SE, CareDx, Inc. (Nasdaq: CDNA), and the Personalized Medicine Coalition. He previously served on the board of directors of MiroMatrix Medical Inc. (Nasdaq: MIRO) from June 2021 until it was acquired by United Therapeutics Corporation in December 2023. Dr. Maag received his PhD from the University of Berlin, Germany, and studied pharmaceutical sciences in Heidelberg and London.
- George W. Bickerstaff, III
-
George W. Bickerstaff, III ，自2014年4月起担任本公司董事。他现为M.M. Dillon & Co., LLC运营总监，他在2005年加入该公司。在加入M.M. Dillon & Co., LLC公司前，他曾担任Novartis International AG多个职位，这是在制药和消费者保健全球领导者，包括从2000年10月至2005年5的任Novartis Pharma AG的首席财务官。1999年12月至2000年9月，他任Workscape执行副总裁兼首席财务官，这是一家员工相关的信息服务提供商。从1998年7月至1999年12月，他担任Uniscribe Professional Services执行副总裁兼首席财务官，这是一家纸张和技术为基础的文档管理解决方案全国性的供应商。 1998年1月至1998年6，他担任Intellisource Group执行副总裁兼首席财务官，这是一家为联邦，州和当地政府及公用事业市场提供信息技术解决方案的供应商。从1997年7月至1997年12月，他担任Cognizant Corporation财务副总裁，这是一家全球性的商业信息服务公司。从1990年1月至1997年6月，他曾担任多个高级财务职位，包括IMS医疗保健财务总监，这是一家在医疗和制药工业领域的全球商业信息服务公司。在此之前，1985年至1989年，任 Dun & Bradstreet财务， 审计和工程职位。从1987至1985，他任任General Electric Company相关财务， 审计和工程职位。 他的非营利性活动，包括担任以下各机构董事，国际疫苗研究所， The Center for Disease Dynamics, Economics & Policy 和The Global Alliance For Vaccines and Immunization。他于1978年获得了罗格斯大学工程学理学士学位及工商管理文学士学位。
George W. Bickerstaff, III has served as a member of Board of Directors since April 2014. Mr. Bickerstaff is currently a Managing Director of M.M. Dillon & Co., LLC, a healthcare and technology boutique investment bank, which he joined in 2005. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005. From December 1999 to September 2000 Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Workscape, Inc., a provider of employee-related information services. From July 1998 to December 1999 Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Uniscribe Professional Services, Inc., a nationwide provider of paper and technology-based document management solutions. From January 1998 to June 1998 Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Intellisource Group, Inc., a provider of information technology solutions to the federal, state and local governments and utility markets. Mr. Bickerstaff has served as a member of the board of directors of Innoviva, Inc. since December 2017 Chair of the Board, Chairman of the Audit Committee and Designated Financial Expert, Cardax, Inc. from June 2014 to 2017 (Chair of the Board, Chair of the Audit Committee and Designated Financial Expert) and InCarda Therapeutics, Inc. since October 2020. Previously, he served as a member of the board of directors of Axovant Sciences Ltd. from February 2018 to February 2020 (Chair of the Audit Committee and Designated Financial Expert); Inovio Pharmaceuticals, Inc. from May 2017 to May 2018 (member of the Audit Committee and Designated Financial Expert); and ARIAD Pharmaceuticals, Inc. from May 2016 to February 2017 (Chair of the Audit Committee and Designated Financial Expert). Mr. Bickerstaff received a Bachelor of Science degree in Engineering and a Bachelor of Arts degree in Business Administration from Rutgers University. - George W. Bickerstaff, III ，自2014年4月起担任本公司董事。他现为M.M. Dillon & Co., LLC运营总监，他在2005年加入该公司。在加入M.M. Dillon & Co., LLC公司前，他曾担任Novartis International AG多个职位，这是在制药和消费者保健全球领导者，包括从2000年10月至2005年5的任Novartis Pharma AG的首席财务官。1999年12月至2000年9月，他任Workscape执行副总裁兼首席财务官，这是一家员工相关的信息服务提供商。从1998年7月至1999年12月，他担任Uniscribe Professional Services执行副总裁兼首席财务官，这是一家纸张和技术为基础的文档管理解决方案全国性的供应商。 1998年1月至1998年6，他担任Intellisource Group执行副总裁兼首席财务官，这是一家为联邦，州和当地政府及公用事业市场提供信息技术解决方案的供应商。从1997年7月至1997年12月，他担任Cognizant Corporation财务副总裁，这是一家全球性的商业信息服务公司。从1990年1月至1997年6月，他曾担任多个高级财务职位，包括IMS医疗保健财务总监，这是一家在医疗和制药工业领域的全球商业信息服务公司。在此之前，1985年至1989年，任 Dun & Bradstreet财务， 审计和工程职位。从1987至1985，他任任General Electric Company相关财务， 审计和工程职位。 他的非营利性活动，包括担任以下各机构董事，国际疫苗研究所， The Center for Disease Dynamics, Economics & Policy 和The Global Alliance For Vaccines and Immunization。他于1978年获得了罗格斯大学工程学理学士学位及工商管理文学士学位。
- George W. Bickerstaff, III has served as a member of Board of Directors since April 2014. Mr. Bickerstaff is currently a Managing Director of M.M. Dillon & Co., LLC, a healthcare and technology boutique investment bank, which he joined in 2005. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005. From December 1999 to September 2000 Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Workscape, Inc., a provider of employee-related information services. From July 1998 to December 1999 Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Uniscribe Professional Services, Inc., a nationwide provider of paper and technology-based document management solutions. From January 1998 to June 1998 Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Intellisource Group, Inc., a provider of information technology solutions to the federal, state and local governments and utility markets. Mr. Bickerstaff has served as a member of the board of directors of Innoviva, Inc. since December 2017 Chair of the Board, Chairman of the Audit Committee and Designated Financial Expert, Cardax, Inc. from June 2014 to 2017 (Chair of the Board, Chair of the Audit Committee and Designated Financial Expert) and InCarda Therapeutics, Inc. since October 2020. Previously, he served as a member of the board of directors of Axovant Sciences Ltd. from February 2018 to February 2020 (Chair of the Audit Committee and Designated Financial Expert); Inovio Pharmaceuticals, Inc. from May 2017 to May 2018 (member of the Audit Committee and Designated Financial Expert); and ARIAD Pharmaceuticals, Inc. from May 2016 to February 2017 (Chair of the Audit Committee and Designated Financial Expert). Mr. Bickerstaff received a Bachelor of Science degree in Engineering and a Bachelor of Arts degree in Business Administration from Rutgers University.
- Michael D. Goldberg
-
Michael D. Goldberg自2011年11月曾担任董事会主席兼董事。他曾担任Nodality公司董事会的董事及主席，这是一家私人的分子诊断公司，并自2011年5月起任其他私人生命科学公司顾问。自1999年以来，他还担任 eHealth董事。从2005年1月至2011年5月，他曾是Mohr Davidow Ventures合伙人，这是一家风险投资公司，他领导在分子诊断领域，个性化医疗和无线医疗生命科学投资。从2000年10月至2004年12月，他经营管理和财务顾问业务。 1995年，他创办OnCare公司，这是一个肿瘤疾病管理公司，并担任董事长，直到2001年8月。并任期首席执行官直到1999年3月。1987年，他创办Axion，这是一家癌症治疗服务公司，并担任首席执行官，直到1995年公司出售。在任职Axion之前，1985年至1987年，他在 Sevin Rosen Management Company合伙人，这是一家风险投资公司，在那里他成立了公司的生命科学的实践，并从1981年至1985年，任 Cetus Corporation企业发展董事。他曾担任多家生物技术和健康科学产业公司的董事，目前担任DNAnexus公司和Nodality公司的执行主席。他曾一系列工业界，学术界和公共政策机构在生物技术和金融领域任董事兼顾问，包括独立的公民监督委员会的委员，该委员会是加州再生医学研究所的咨询委员会。西部风险资本家协会会员，哈佛中心遗传学和基因组学咨询委员会委员，伯克利中心法律与技术，以及加州大学旧金山分校中心平移和政策研究的个体化医学的董事会。他获得Brandeis大学文学士和斯坦福大学商学院工商管理硕士学位。
Michael D. Goldberg has served as a member of eHealth, Inc. Board of Directors since November 2011 and as eHealth, Inc. Lead Independent Director since January 2020. Mr. Goldberg has served as a director and chairman of the Board of Directors of DNAnexus, Inc., a cloud-based genome informatics and data management company, and as an advisor to other private life science companies since May 2011. Mr. Goldberg has also served on the Board of Directors for eHealth, Inc. since 1999. From January 2005 to May 2011 Mr. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine and digital healthcare. In 1987 Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as its Chief Executive Officer until its sale in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm of Sevin Rosen Management Company from 1985 to 1987 where he established the firm's life science practice, and director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the Board of Directors of numerous companies in the biotech and health sciences industry. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic and public policy institutions in biotechnology and finance, including the Board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the Board of the Western Association of Venture Capitalists, the Advisory Boards for the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, the UCSF Center for Translational and Policy Research on Personalized Medicine and the Stanford Distinguished Careers Institute. Mr. Goldberg holds a B.A. from Brandeis University and an M.B.A. from the Stanford Graduate School of Business. - Michael D. Goldberg自2011年11月曾担任董事会主席兼董事。他曾担任Nodality公司董事会的董事及主席，这是一家私人的分子诊断公司，并自2011年5月起任其他私人生命科学公司顾问。自1999年以来，他还担任 eHealth董事。从2005年1月至2011年5月，他曾是Mohr Davidow Ventures合伙人，这是一家风险投资公司，他领导在分子诊断领域，个性化医疗和无线医疗生命科学投资。从2000年10月至2004年12月，他经营管理和财务顾问业务。 1995年，他创办OnCare公司，这是一个肿瘤疾病管理公司，并担任董事长，直到2001年8月。并任期首席执行官直到1999年3月。1987年，他创办Axion，这是一家癌症治疗服务公司，并担任首席执行官，直到1995年公司出售。在任职Axion之前，1985年至1987年，他在 Sevin Rosen Management Company合伙人，这是一家风险投资公司，在那里他成立了公司的生命科学的实践，并从1981年至1985年，任 Cetus Corporation企业发展董事。他曾担任多家生物技术和健康科学产业公司的董事，目前担任DNAnexus公司和Nodality公司的执行主席。他曾一系列工业界，学术界和公共政策机构在生物技术和金融领域任董事兼顾问，包括独立的公民监督委员会的委员，该委员会是加州再生医学研究所的咨询委员会。西部风险资本家协会会员，哈佛中心遗传学和基因组学咨询委员会委员，伯克利中心法律与技术，以及加州大学旧金山分校中心平移和政策研究的个体化医学的董事会。他获得Brandeis大学文学士和斯坦福大学商学院工商管理硕士学位。
- Michael D. Goldberg has served as a member of eHealth, Inc. Board of Directors since November 2011 and as eHealth, Inc. Lead Independent Director since January 2020. Mr. Goldberg has served as a director and chairman of the Board of Directors of DNAnexus, Inc., a cloud-based genome informatics and data management company, and as an advisor to other private life science companies since May 2011. Mr. Goldberg has also served on the Board of Directors for eHealth, Inc. since 1999. From January 2005 to May 2011 Mr. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine and digital healthcare. In 1987 Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as its Chief Executive Officer until its sale in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm of Sevin Rosen Management Company from 1985 to 1987 where he established the firm's life science practice, and director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the Board of Directors of numerous companies in the biotech and health sciences industry. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic and public policy institutions in biotechnology and finance, including the Board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the Board of the Western Association of Venture Capitalists, the Advisory Boards for the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, the UCSF Center for Translational and Policy Research on Personalized Medicine and the Stanford Distinguished Careers Institute. Mr. Goldberg holds a B.A. from Brandeis University and an M.B.A. from the Stanford Graduate School of Business.
高管简历
中英对照 | 中文 | 英文- Nathan Smith
Nathan Smith，于2024年11月至2025年8月期间担任直接面向消费者的品牌规模平台Win Brands Group的首席财务官，于2023年10月至2025年8月期间担任基于云的诊断开发商Inmedix，Inc.的首席财务官和战略顾问。史密斯先生还于2024年5月与他人共同创立了基因编辑技术开发商Cassette Genomics，Inc.。Smith先生此前曾于2024年2月至2024年10月期间担任门诊物理治疗提供商Mountain Land Physical Therapy Partners的首席财务官，并于2022年7月至2023年9月期间担任神经技术公司BlackRock Microsystems，Inc.，d.B.a. BlackRock Neurotech的首席财务官。在加入贝莱德神经科技之前，Smith先生曾于2008年1月至2022年6月在基因检测和精准医疗公司Myriad Genetics, Inc.任职十四年，担任越来越多的职责，最近的职位是2021年5月至2022年6月担任该公司投资者关系与财务高级副总裁，2018年7月至2021年5月担任该公司财务与财务高级副总裁。Smith先生于2002年获得杨百翰大学金融学商业学士学位，并于2003年获得弗吉尼亚大学会计学硕士学位。
Nathan Smith,served as the Chief Financial Officer of Win Brands Group, a direct-to-consumer brand scale platform, from November 2024 to August 2025 and as the Chief Financial Officer and Strategic Advisor of Inmedix, Inc., a developer of cloud-based diagnostics, from October 2023 to August 2025. Mr. Smith also co-founded Cassette Genomics, Inc., a developer of gene editing technology, in May 2024. Mr. Smith previously served as the Chief Financial Officer of Mountain Land Physical Therapy Partners, an outpatient physical therapy provider, from February 2024 to October 2024 and as the Chief Financial Officer of Blackrock Microsystems, Inc., d.b.a. Blackrock Neurotech, a neurotechnology company, from July 2022 until September 2023. Prior to Blackrock Neurotech, Mr. Smith served in roles of increasing responsibility over fourteen years with Myriad Genetics, Inc., a genetic testing and precision medicine company, from January 2008 to June 2022, where his most recent positions were as its Senior Vice President of Investor Relations & Treasury from May 2021 to June 2022 and as its Senior Vice President of Finance & Treasury from July 2018 to May 2021. Mr. Smith received a Bachelor of Business in Finance from Brigham Young University in 2002 and an M.S. in Accounting from the University of Virginia in 2003.- Nathan Smith，于2024年11月至2025年8月期间担任直接面向消费者的品牌规模平台Win Brands Group的首席财务官，于2023年10月至2025年8月期间担任基于云的诊断开发商Inmedix，Inc.的首席财务官和战略顾问。史密斯先生还于2024年5月与他人共同创立了基因编辑技术开发商Cassette Genomics，Inc.。Smith先生此前曾于2024年2月至2024年10月期间担任门诊物理治疗提供商Mountain Land Physical Therapy Partners的首席财务官，并于2022年7月至2023年9月期间担任神经技术公司BlackRock Microsystems，Inc.，d.B.a. BlackRock Neurotech的首席财务官。在加入贝莱德神经科技之前，Smith先生曾于2008年1月至2022年6月在基因检测和精准医疗公司Myriad Genetics, Inc.任职十四年，担任越来越多的职责，最近的职位是2021年5月至2022年6月担任该公司投资者关系与财务高级副总裁，2018年7月至2021年5月担任该公司财务与财务高级副总裁。Smith先生于2002年获得杨百翰大学金融学商业学士学位，并于2003年获得弗吉尼亚大学会计学硕士学位。
- Nathan Smith,served as the Chief Financial Officer of Win Brands Group, a direct-to-consumer brand scale platform, from November 2024 to August 2025 and as the Chief Financial Officer and Strategic Advisor of Inmedix, Inc., a developer of cloud-based diagnostics, from October 2023 to August 2025. Mr. Smith also co-founded Cassette Genomics, Inc., a developer of gene editing technology, in May 2024. Mr. Smith previously served as the Chief Financial Officer of Mountain Land Physical Therapy Partners, an outpatient physical therapy provider, from February 2024 to October 2024 and as the Chief Financial Officer of Blackrock Microsystems, Inc., d.b.a. Blackrock Neurotech, a neurotechnology company, from July 2022 until September 2023. Prior to Blackrock Neurotech, Mr. Smith served in roles of increasing responsibility over fourteen years with Myriad Genetics, Inc., a genetic testing and precision medicine company, from January 2008 to June 2022, where his most recent positions were as its Senior Vice President of Investor Relations & Treasury from May 2021 to June 2022 and as its Senior Vice President of Finance & Treasury from July 2018 to May 2021. Mr. Smith received a Bachelor of Business in Finance from Brigham Young University in 2002 and an M.S. in Accounting from the University of Virginia in 2003.
- John Walter Hanna, Jr.
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jessica Meng
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Keith Kennedy
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jeff Novack
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介